Upcoming events
Where health tech
meets real change.
Workshops, pitch sessions, networking and conferences — connecting startups, clinicians, and investors across the Danish health tech ecosystem.
30SEPInvestment & FundingUnlocking European & Danish funding09:00–12:00 · Health Tech HubRead more
A hands-on workshop with Catalyze
Non-dilutive funding can accelerate growth for health and life sciences companies — but figuring out which of the European and Danish programmes actually fits, and what it takes to be a competitive applicant, is its own puzzle.
Why attend
By the end, you’ll know which programmes — Eureka Eurostars, the EIC tracks, the EUopStart voucher, Denmark’s Grand Solutions — actually fit your company, what evaluators look for and the pitfalls that sink applications, and the practical next steps for a realistic funding roadmap.
Who it’s for
Health tech companies looking for funding or grants, whether you’ve applied many times before, or this is your first.
Format
Interactive throughout, with live quizzes, polls, and Q&A (and possibly a prize on the line). Afterwards, book an optional 1:1 with the Catalyze team to talk through your own eligibility and funding strategy.
Registration opens soon — check back closer to the date.
16SEPInvestment & FundingMarket AccessScale Your Business: Pricing, reimbursement & investment readiness13:00–15:30 · TalentGarden, Danneskiold-Samsøes Allé 41, 1434 KøbenhavnSign up
Market access strategy, pricing logic, and reimbursement positioning have moved from the back office to the boardroom. Whether you’re a seed-stage health tech defining your first evidence roadmap or a late-stage company preparing for partnership or exit, how you think about reimbursement pathways, value-based pricing, and payer narratives is no longer a regulatory checkbox – it’s a core determinant of company valuation, scalability, and investor confidence.
This workshop brings together founders, business development leaders, and market access professionals to explore a fundamental shift in how pricing and reimbursement should be aligned with how investors evaluate ventures. Early reimbursement thinking, evidence strategy, and pricing logic are now read as signals of commercial maturity and risk management – long before a product reaches its first payer negotiation.
Equally, a credible pricing strategy – one that aligns clinical evidence, health economic models, and willingness-to-pay across payer segments – is increasingly scrutinised in due diligence and partnership discussions.
We’ll examine how reimbursement architecture, pricing narrative, and market access strategy collectively shape commercialisation and funding decisions, influence partnership terms, and define exit potential – and what it takes to speak this language fluently at every stage of your company’s growth.
Who it’s for
Founders, BD leaders, and market access professionals in health tech and MedTech companies – from seed stage to late stage.